PRF Technologies Ltd. (PRFX) - Form 20-F Summary
Business Context and Reporting Period
Company: PRF Technologies Ltd. (formerly PainReform Ltd.)
Reporting Period: Fiscal year ended December 31, 2025
Jurisdiction: Israel (Foreign Private Issuer)
Listing: Nasdaq Capital Market (Symbol: PRFX)
Accounting Basis: U.S. GAAP
PRF Technologies is a diversified technology innovation company with two primary segments: Clinical Development (specialty pharmaceuticals) and Solar Energy (AI-driven analytics). In March 2025, the company acquired the DeepSolar AI solar analytics platform. In August 2025, it acquired a controlling interest in LayerBio Inc., a biotechnology company focused on ophthalmic drug delivery (OcuRing-K). The company has never generated significant revenue and remains in a development stage.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (US$ Thousands) | 2024 (US$ Thousands) | 2023 (US$ Thousands) |
|---|---|---|---|
| Revenues | 17 | 0 | 0 |
| Net Loss | (4,838) | (14,588) | (9,344) |
| Operating Loss | (5,122) | (14,673) | (9,584) |
| Research & Development Expenses | (1,136) | (11,705) | (6,035) |
| General & Administrative Expenses | (3,011) | (2,968) | (3,549) |
| Cash & Cash Equivalents (End of Period) | 3,150 | 4,271 | 8,036 |
| Accumulated Deficit | (61,289) | (56,451) | (41,863) |
| Net Cash Used in Operating Activities | (3,955) | (12,621) | (6,679) |
Note: Revenue of $17k is attributed to the newly acquired DeepSolar segment. The significant decrease in R&D expenses in 2025 compared to 2024 is primarily due to the completion of the Phase 3 clinical trial for PRF-110 in 2024.
Material Changes vs. Prior Period
- Strategic Acquisitions: Acquired DeepSolar (AI solar analytics) in March 2025 for approximately $7.3 million in equity consideration. Acquired a controlling interest in LayerBio Inc. (ophthalmic drug delivery) in August 2025.
- Clinical Trial Outcome: In December 2024, the Phase 3 clinical trial for PRF-110 (post-surgical pain) failed to meet its primary endpoint. Consequently, R&D activities for PRF-110 were scaled back, and the company shifted focus to OcuRing-K.
- Capital Structure: Raised approximately $4.0 million in gross proceeds via an At-The-Market (ATM) program in 2025. Effected a 1-for-5 reverse share split in February 2026 (subsequent to period end).
- Financial Performance: Net loss decreased by approximately 67% year-over-year, driven by reduced clinical trial expenditures. However, cash reserves declined from $4.3 million in 2024 to $3.2 million in 2025.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: The independent auditor has issued an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. The company has an accumulated deficit of $61.3 million and expects to incur losses for the foreseeable future. Management plans to raise additional capital through equity offerings or strategic partnerships, but there is no assurance of success.
Outlook:
- Clinical: Focus is on advancing OcuRing-K (LayerBio) toward Phase II clinical trials. PRF-110 is no longer the primary clinical focus.
- Solar: DeepSolar is in early commercialization stages. The company expects to generate revenue from this segment but faces competition and market adoption risks.
Key Risks:
- Liquidity: Cash on hand ($3.2 million) may not be sufficient to fund operations for the next 12 months without additional financing.
- Geopolitical: Operations are based in Israel. Ongoing regional conflicts (Israel-Hamas, Israel-Hezbollah, tensions with Iran) pose risks to operations, supply chains, and employee availability.
- Internal Controls: The company identified a material weakness in internal control over financial reporting due to insufficient finance staff and incomplete segregation of duties.
- Regulatory: Risk of failure in future clinical trials for OcuRing-K and potential delisting from Nasdaq if market value or equity requirements are not met.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash reserves ($3.2M) against projected burn rates for OcuRing-K development and DeepSolar commercialization.
- Financing Plans: Assess the feasibility and terms of upcoming capital raises required to address the "substantial doubt" going concern warning.
- Internal Controls: Review the remediation plan for the material weakness in internal controls over financial reporting.
- Clinical Progress: Monitor the timeline and results of the upcoming Phase II trial for OcuRing-K.
- Geopolitical Exposure: Evaluate the impact of the security situation in Israel on the company's ability to retain key personnel and maintain operations.
- DeepSolar Revenue: Verify the actual revenue generation and customer acquisition rates for the DeepSolar segment, as it is the only current revenue source.